What It Is
PT-141 is the widely used research and marketing name for bremelanotide, a synthetic peptide that acts as a melanocortin receptor agonist. In the United States it is the active ingredient in Vyleesi, a prescription drug the FDA approved in 2019 for a narrow indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.[1] That approval is specific to Vyleesi's formulation, dose, and labeled population — it does not extend to every product sold online under the "PT-141" name.
This distinction matters because bremelanotide is chemically related to earlier melanocortin research compounds studied for pigmentation and sexual response, and "PT-141" is often used loosely online to describe unregulated peptide vials marketed for broader libido or performance claims that fall outside the approved label.
How It Works
Bremelanotide binds melanocortin receptors, a receptor family also involved in pigmentation and energy balance, but the FDA label states plainly that the exact mechanism by which it improves HSDD symptoms is not established.[1] What is known is that it acts centrally, through signaling pathways in the brain, rather than on local genital blood flow.
This sets it apart from phosphodiesterase type 5 (PDE5) inhibitors like sildenafil and tadalafil, which work through vasodilation in penile tissue. A central, desire-related mechanism and a peripheral, blood-flow mechanism are not interchangeable, which is one reason bremelanotide is not indicated for erectile dysfunction.
What the Research Shows
The core evidence for bremelanotide comes from two randomized, placebo-controlled Phase 3 trials, often referred to as the RECONNECT studies, in premenopausal women diagnosed with acquired, generalized HSDD.[2] Across both trials, bremelanotide produced statistically significant improvements in validated measures of sexual desire and related distress compared with placebo. It did not, however, meaningfully increase the number of satisfying sexual events — a distinction the FDA label itself highlights.
Evidence for use in men, postmenopausal women, or as a general performance enhancer is comparatively thin, resting mainly on earlier mechanistic and animal research on melanocortin agonists rather than dedicated approval-grade human trials in those populations.
Safety & Side Effects
- Nausea is the most commonly reported adverse effect, frequent enough that some trial participants used anti-nausea medication or discontinued treatment.
- Flushing, injection-site reactions, headache, vomiting, and a transient rise in blood pressure with a corresponding drop in heart rate are documented on the label.[1]
- Focal hyperpigmentation can occur, especially with more frequent dosing, and the label advises stopping treatment if it develops.
- Bremelanotide is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and it can reduce absorption of oral naltrexone.
Long-term safety data outside the approved dosing schedule — no more than one dose per 24 hours and eight per month — are limited, and this safety profile cannot be assumed to apply to unregulated, non-FDA-reviewed PT-141 products sold online.
Regulatory Status
Bremelanotide is FDA-approved, but only as Vyleesi, for acquired, generalized HSDD in premenopausal women, under a defined dosing schedule.[1] The label explicitly excludes postmenopausal women and men, and states that bremelanotide is not indicated to enhance sexual performance.
Products marketed online as "PT-141 peptide" for broader libido, male sexual function, or general enhancement are not the same as the approved drug. Compounded or research-grade versions fall outside FDA review for safety, effectiveness, and manufacturing quality, so equivalence to Vyleesi should never be assumed.[3]